Benefits of using bisphosphonates drugs

Bisphosphonates drugs for osteoporosis (Aclasta, Actonel, Didrocal, Fosamax, Fosavance): A small but increased risk of hip fractures uncommon

Update Information December 19, 2011

Ottawa - Health Canada updated with Canadians to respect it with bisphosphonates drugs used to treat osteoporosis and the risk of rare but serious type of femur fracture known as atypical fracture of the femur. Atypical fractures of the femur is very rare, they seem less than 1% of all hip and hip fractures in general. Review of Health Canada's experience shows lasix to pass drug test a slightly increased risk of this type of fracture using bisphosphonates. Although higher risk when using bisphosphonates is still very small. Benefits of using bisphosphonates drugs in preventing fractures associated with osteoporosis outweigh the risk of hip fractures atypical. Bisphosphonates prescription drugs used to treat osteoporosis in men and postmenopausal women. They can also be used to prevent osteoporosis in postmenopausal women and in patients taking glucocorticoids. Osteoporosis is loss of bone density often associated with aging that can cause painful fractures, disability and deformity. Bisphosphonates have a long history of effective use in the treatment of osteoporosis and prevention. Information about the product brand name drugs bisphosphonates has been updated with new warnings and precautions for this risk, including possible signs of hip fracture atypical that patients and health professionals must follow. Update the tags for generic drugs will follow. (See below >> << Canada).

Atypical femur fractures can occur with minimal or no effect on hip area, and can occur in both legs in one person. Signs of potential fracture dull, aching pain in the hips, thighs or groin. Direct damage can take weeks or months to become complete fractures. Patients who are currently taking or have taken bisphosphonates drugs in the past and who will notice new or unusual pain in the hip, groin or hip should talk with your doctor as this may be a sign of atypical fracture of the femur. Patients should not stop taking their bisphosphonates drugs, if the advice of your doctor. Health Canada recommends that consumers should consult with your doctor, practitioner questions or concerns regarding the use of these products. Health care workers should be aware of the risk of atypical femoral fractures in patients taking bisphosphonates. As noted in the updated product information, health professionals should assess patients who reported new pain hips, thighs or groin, to exclude a partial destruction of the hip. Patients with atypical hip fracture should be evaluated for possible signs of a fracture in the other leg. Cessation of bisphosphonates therapy should be considered pending assessment of the patient or the risk / benefit from its use. Physicians are reminded that the need for continued therapy should be periodically re-evaluated bisphosphonates. Drug label or product monographs, contain important information purposes and security for health workers and patients, and are available by searching Health Canada. To report suspected adverse reactions to these products or other health, please contact the Canada Vigilance Program Health Canada toll-free phone 1-866-234-2345 or complete the fax

Internet-mail (Ottawa , ON, Address Locator 0701E

Bisphosphonates are drugs in a particular strength and dosage, and come in the form of liquid or tablets for oral administration or as a solution for injection media inquiries. public inquiries.